Efficacy and Safety of biosimilar to Crohn's disease and ulcerative colitis: prospective cohort observational study
Not Applicable
Recruiting
- Conditions
- Crohn's disease and ulcerative colitis
- Registration Number
- JPRN-UMIN000053025
- Lead Sponsor
- Kurashiki Central Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients without definite diagnosis of Crohn's disease or ulcerative colitis. 2. Patients who have previously received either Infliximab BS or Adalimumab BS. 3. Patients who are judged by the researchers to be unsuitable as research subjects.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical remission rate after 1 year and 3 years
- Secondary Outcome Measures
Name Time Method